Patents by Inventor Michael Riis Hansen

Michael Riis Hansen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for modulating beta chain mediated immunity
    Patent number: 11965024
    Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Grant
    Filed: September 10, 2021
    Date of Patent: April 23, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Iqbal S. Grewal, Sanjaya Singh, Michael Riis Hansen
  • Bioengineered T cell mediated immunity, materials and other methods for modulating cluster of differentiation IV and/or VIII
    Patent number: 11926667
    Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.
    Type: Grant
    Filed: October 12, 2021
    Date of Patent: March 12, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen
  • COMPOSITIONS AND METHODS FOR MODULATING DELTA GAMMA CHAIN MEDIATED IMMUNITY
    Publication number: 20220125947
    Abstract: Provided herein, in certain aspects, are antibodies that bind to T cell receptor (TCR) V?9 (TRGV9), TCR V?2 (TRDV2), or the TCR gamma/delta constant region (TRGDC), as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.
    Type: Application
    Filed: October 27, 2021
    Publication date: April 28, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Iqbal S. GREWAL, Sanjaya SINGH, Michael Riis HANSEN
  • BIOENGINEERED T CELL MEDIATED IMMUNITY, MATERIALS AND OTHER METHODS FOR MODULATING CLUSTER OF DIFFERENTIATION IV &/OR VIII
    Publication number: 20220112288
    Abstract: Provided herein, in certain aspects, are antibodies that bind to CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are antibodies that bind to CD4, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD4 and CD8, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making the antibodies are also provided.
    Type: Application
    Filed: October 12, 2021
    Publication date: April 14, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Sanjaya SINGH, Iqbal S. GREWAL, Michael Riis HANSEN
  • IMMUNE TARGETING MOLECULES AND USES THEREOF
    Publication number: 20220089736
    Abstract: Provided herein, in certain aspects, are antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Also provided herein, in certain aspects, are multispecific antibodies that bind to CD28, as well as recombinant cells containing the vectors, and compositions comprising the antibodies. Methods of making and using the antibodies are also provided.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Iqbal S. GREWAL, Michael Riis HANSEN, Rajkumar GANESAN, Sanjaya SINGH
  • MULTI-SPECIFIC IMMUNE TARGETING MOLECULES AND USES THEREOF
    Publication number: 20220089737
    Abstract: Provided herein are trispecific antibodies or antigen binding fragments thereof that bind to V?17, CD28 and another target (e.g., a cancer antigen, such as BCMA or PSMA) are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Michael Riis HANSEN, Iqbal S. GREWAL, Sanjaya SINGH
  • METHODS AND COMPOSITIONS FOR MODULATING BETA CHAIN MEDIATED IMMUNITY
    Publication number: 20220089731
    Abstract: Anti-V?17 antibodies or antigen binding fragments thereof are described. Also described are nucleic acids encoding the antibodies, compositions comprising the antibodies, methods of producing the antibodies, and methods of using the antibodies for treating or preventing diseases.
    Type: Application
    Filed: September 10, 2021
    Publication date: March 24, 2022
    Applicant: JANSSEN BIOTECH, INC.
    Inventors: Rajkumar GANESAN, Iqbal S. GREWAL, Sanjaya SINGH, Michael Riis HANSEN
  • MATERIALS AND METHODS FOR IN VIVO BIOLOGICAL TARGETING
    Publication number: 20210214440
    Abstract: An isolated molecule, comprising: a first antigen binding domain and a second antigen binding domain, wherein the first antigen binding domain specifically binds CD8 and the second antigen binding domain specifically binds a T cell receptor (TCR) complex.
    Type: Application
    Filed: December 17, 2020
    Publication date: July 15, 2021
    Applicant: Janssen Biotech, Inc.
    Inventors: Rajkumar Ganesan, Sanjaya Singh, Iqbal S. Grewal, Michael Riis Hansen